Pharma's Almanac

We had the opportunity to interview Jayne Shaw, Co-Founder and Executive Chair of BCAL Diagnostics, as part of Road to the Max: Australia. BCAL Diagnostics is a biotechnology screening and diagnostic company focused on revolutionizing breast cancer detection. Jayne shared the company’s mission to achieve early and accurate diagnoses, with the goal of facilitating early intervention and ultimately improving outcomes for women. Through their innovative approach, BCAL Diagnostics is dedicated to advancing breast cancer screening technology and empowering women with better health outcomes. Thank you, Jayne, for sharing BCAL’s inspiring work in the fight against breast cancer! Check out the full interview and the rest of the road trip: https://lnkd.in/eG6HWq5U John Hurrell Ph.D. | Shane Ryan | Simon Preston | Alexandra Feetham | Kim Kirkham | Merilyn Sleigh #roadtothemax #madmax #pharmaindustry #pharma #lifescience #biotech #clinicaltrials #australia

The 2025 Pharma's Almanac Media Kit Has Landed! Looking to boost your brand in the pharma, biotech, and life science sectors? The 2025 Media Kit has everything you need to connect with industry leaders, showcase thought leadership, and leverage exclusive pricing and benchmarking insights. Pharma's Almanac has you covered whether you're looking for prime ad placements, content and thought leadership packages, or the inside track on industry trends. Want to get in on the action? (....of course, you do ;-) Drop me a line at emilee@pharmasalmanac.com for all the details, or check us out at www.pharmasalmanac.com #pharmamarketing #biotechnews #thoughtleadership #industryinsights #lifesciences #mediakit #brandingstrategy #pharmasalmanac #pharmabusiness #2025trends #biotech #cdmo #cro #pricing #publishing #insight #content #advertising #trends #benchmarking #marketing #pharma #leaders

𝑨𝒃𝒃𝑽𝒊𝒆 𝒕𝒐 𝑨𝒄𝒒𝒖𝒊𝒓𝒆 𝑨𝒍𝒊𝒂𝒅𝒂 𝑻𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄𝒔, 𝑺𝒕𝒓𝒆𝒏𝒈𝒕𝒉𝒆𝒏𝒊𝒏𝒈 𝑭𝒐𝒄𝒖𝒔 𝒊𝒏 𝑨𝒍𝒛𝒉𝒆𝒊𝒎𝒆𝒓'𝒔 𝑫𝒊𝒔𝒆𝒂𝒔𝒆 𝒂𝒏𝒅 𝑵𝒆𝒖𝒓𝒐𝒔𝒄𝒊𝒆𝒏𝒄𝒆 𝑷𝒊𝒑𝒆𝒍𝒊𝒏𝒆 🧠🧪 AbbVie and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel technology to address challenging central nervous system diseases. 🔗 Read more here: https://lnkd.in/eCx2_9yW #AlzheimersResearch #Pharma #Biotech #AliadaTherapeutics

𝑵𝒂𝒗𝒊𝒈𝒂𝒕𝒊𝒏𝒈 𝒕𝒉𝒆 𝑪𝒐𝒎𝒑𝒍𝒆𝒙𝒊𝒕𝒊𝒆𝒔 𝒐𝒇 𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑻𝒓𝒊𝒂𝒍𝒔 🚀 In the ever-evolving landscape of oncology, clinical trials are becoming increasingly complex. Colin Hayward from ERGOMED dives deep into how the company is uniquely positioned to support patients, sites, and investigators in overcoming these challenges. 💡💊 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐡𝐞𝐫𝐞: https://lnkd.in/eJqxxNrQ #Oncology #ClinicalTrials #PatientSupport #HealthcareInnovation #ErgoMed

We had the privilege of interviewing Dr. Rachel de las Heras, Ultrasound Product Development Manager at the UQ Queensland Brain Institute (QBI), as part of our Road to the Max: Australia journey. Located on The University of Queensland campus in Brisbane, QBI is dedicated solely to understanding the fundamentals of how the brain works, with a mission to translate this knowledge into new treatments. Dr. de las Heras shared insights into QBI’s groundbreaking research, which paves the way for innovative therapies for brain diseases, neurodegenerative conditions, psychiatric disorders, and beyond. Her team’s work exemplifies the incredible potential of neuroscience to improve patient outcomes and tackle some of the most challenging health issues of our time. Thank you, Rachel, for an inspiring conversation about the future of brain research! Check out the full interview and the rest of the road trip: https://lnkd.in/ejnbfDgb Pankaj Sah | Beverley Trivett AM | Andrea Markey #roadtothemax #madmax #pharmaindustry #pharma #lifescience #biotech #clinicaltrials #australia #brisbane

𝑻𝑹𝑬𝑴𝑭𝒀𝑨® 𝒊𝒔 𝒕𝒉𝒆 𝒇𝒊𝒓𝒔𝒕 𝒂𝒏𝒅 𝒐𝒏𝒍𝒚 𝑰𝑳-23 𝒊𝒏𝒉𝒊𝒃𝒊𝒕𝒐𝒓 𝒕𝒐 𝒅𝒆𝒎𝒐𝒏𝒔𝒕𝒓𝒂𝒕𝒆 𝒓𝒐𝒃𝒖𝒔𝒕 𝒓𝒆𝒔𝒖𝒍𝒕𝒔 𝒘𝒊𝒕𝒉 𝒓𝒆𝒈𝒊𝒎𝒆𝒏. 🌟🩺 TREMFYA® from Johnson & Johnson could become the first IL-23 treatment to offer both a subcutaneous and intravenous induction regimen for patients living with Crohn's disease, pending FDA approval. 🚀 Read more here: https://lnkd.in/giTt7Pzn #CrohnsDisease #InflammatoryBowelDisease #HealthcareInnovation #TREMFYA

We had the pleasure of sitting down with Brent Owens, Co-Founder & Deputy CEO of Vitrafy Life Sciences, for an insightful interview in downtown Melbourne as part of Road to the Max: Australia. Brent shared how Vitrafy is shaping the future of biopharma with its vertically integrated cryopreservation solutions that ensure the quality and safety of biomaterials. With the rapid rise of CAR-T cell therapies over the past two years, the need for specialized storage solutions has never been greater. Vitrafy's focus on retaining the quality of biomaterials, particularly within cell and gene therapies, plays a crucial role in fortifying the biopreservation supply chain so that these life-changing products can reach patients safely and efficiently. Thank you, Brent, for sharing your expertise and shedding light on the importance of biopreservation in advancing healthcare. Check out the full interview and the rest of the road trip: https://lnkd.in/eTA4rbn2 Sean Cameron | Kate Munnings | Dr Dave G. | Sonia Petering | James Groom #roadtothemax #madmax #pharmaindustry #pharma #lifescience #biotech #clinicaltrials #australia

We're excited to share our interview with Michael Moussourakis, VP of Strategy at Alconox Inc.! This conversation was particularly special as it marked the very first interview of Road to the Max: Australia — and brought us full circle, as Michael also kicked off our Road to 50 States journey back in 2021. Beyond warm wishes, Michael gave us a deep dive into the emerging technologies that are transforming the pharmaceutical landscape, particularly those addressing Australia's alarmingly high rates of skin cancer. Michael and his team at Alconox are at the forefront of cleaning technology, helping pharma manufacturers and innovators ensure that their products remain safe, contaminant-free, and meet regulatory standards. From sunscreens to skincare, Alconox plays a critical role in facilitating the manufacturing processes that protect patients from conditions like melanoma and carcinoma. Thank you, Michael, for your insights and partnership over the years! Check out the full interview and the rest of the road trip: https://lnkd.in/eGy3E9Hg Michelle Modica | Elliot Lebowitz | Malcolm McLaughlin | Matthew Rasulo | Stacy Silverstein, PMP | Doug Patrick #roadtothemax #madmax #pharmaindustry #pharma #lifescience #biotech #clinicaltrials #australia

We had a great interview with Mark W. Womack, CEO of BioCina, during our Road to the Max: Australia journey. BioCina, a specialized CDMO for biotherapeutics, recently expanded into Australia, drawn by the country’s supportive government policies, strong infrastructure, and universities’ commitment to advancing clinical trials. Mark shared BioCina’s excitement about this expansion, as the company plans to add mammalian production capabilities alongside their existing microbial, plasmid DNA, and mRNA capabilities. BioCina’s growth reflects Australia’s increasing role in global biotherapeutics development, and we’re thrilled to see what the future holds for their innovative work. Thank you, Mark, for sharing BioCina’s vision and the promising landscape of biopharma in Australia! Check out the full interview and the rest of the road trip: https://lnkd.in/ePhPTA-a Michael Tsaconas | Jan Bekker | Anthony Morgan | Rik Quaghebeur | Melissa El Khouri | Alex Pomerantz #roadtothemax #madmax #pharmaindustry #pharma #lifescience #biotech #clinicaltrials #australia

We had an insightful conversation with John Wrenn, Director of Operations, Australia & New Zealand at CAI during our Road to the Max: Australia journey. CAI brings its expertise in complex project management, no-code technology, commissioning, compliance, training, and operational workflows to support clients in Australia and the APAC region. John shared how CAI helps companies navigate the regulatory landscape for clinical trials, ensuring their projects run smoothly from start to finish. By providing critical support across the entire operational workflow, CAI is helping life sciences companies bring their innovations to market efficiently and compliantly. Thank you, John, for sharing how CAI is driving excellence in clinical trials and project management! Check out the full interview and the rest of the road trip: https://lnkd.in/eSrfkExj Mike Martin | Roger Ouimet | Chas Carabasi | Andrew Bohlmann | Joseph Nardella | Richard Tree, D.Eng. | Alice Redmond | Sean Sullivan | Joe Robinson, QCxP, CPIP | Edward Horgan | Angel Estrada | Kirk Calhoun | Kelly Smeltzer | Susan Warren | Luis Felipe Mercado | David Tremain, PMP #roadtothemax #madmax #pharmaindustry #pharma #lifescience #biotech #clinicaltrials #australia